BIO-TECHNE CORP
TECHNASDAQTrading Snapshot
- Day Range
- $71.87 β $72.95
- 52-Week Range
- $43.20 β $72.69
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 156.6M
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.22B
- Last Q Revenue
- $321M
- P/E Ratio
- 62.0
- P/S Ratio
- 9.3x
- EPS (TTM)
- $1.17
- Dividend Yield
- 0.44%
- Dilution (1yr)
- +0.0%
Why Investors Own TECH
- βHigh-growth profile β revenue up -3.1% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 12% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIO-TECHNE CORP
TECHAbout BIO-TECHNE CORP
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
BIO-TECHNE CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TECH price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BIO-TECHNE CORP announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.